Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
5.46
-0.08 (-1.44%)
At close: Apr 28, 2026, 4:00 PM EDT
5.67
+0.21 (3.82%)
After-hours: Apr 28, 2026, 5:12 PM EDT
Verastem Employees
Verastem had 102 employees as of December 31, 2025. The number of employees increased by 24 or 30.77% compared to the previous year.
Employees
102
Change (1Y)
24
Growth (1Y)
30.77%
Revenue / Employee
$303,078
Profits / Employee
-$2,053,637
Market Cap
479.62M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Lyell Immunopharma | 300 |
| ADC Therapeutics | 193 |
| enGene Therapeutics | 82 |
| Upstream Bio | 75 |
| Tectonic Therapeutic | 60 |
| AgomAb Therapeutics NV | 58 |
| Fulcrum Therapeutics | 55 |
VSTM News
- 5 days ago - Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 - Business Wire
- 18 days ago - Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers - Business Wire
- 26 days ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 - Business Wire
- 6 weeks ago - Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers - Business Wire
- 7 weeks ago - Verastem Earnings Call Transcript: Q4 2025 - Transcripts
- 7 weeks ago - Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates - Business Wire
- 2 months ago - Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Business Wire